[Pubmed] Rethinking rituximab in neuroimmunology: Real-world efficacy, cost-effectiveness, and long-term remission
Posté : 28 févr. 2026 12:00
J Neuroimmunol. 2026 Feb 16;415:578891. doi: 10.1016/j.jneuroim.2026.578891. Online ahead of print.
ABSTRACT
This short communication reviews the long-term use of rituximab (RTX) in neuroimmunological disease and presents a case of chronic inflammatory demyelinating polyneuropathy (CIDP) achieving sustained remission after rituximab therapy. A 10-year retrospective review of 40 patients treated with RTX at a South African quaternary neurology unit demonstrated consistent efficacy, durable safety, and significant cost savings compared to conventional immunotherapies. In addition, a patient with refractory childhood-onset CIDP achieved complete and enduring remission following RTX administration, with normal functional recovery and discontinuation of all immunotherapy. This report highlights the clinical and economic rationale for RTX as a long-term disease-modifying therapy in immune-mediated neurological disorders and argues for its earlier integration into standard treatment protocols, especially in resource-limited settings.
PMID:41762916 | DOI:10.1016/j.jneuroim.2026.578891
Source: https://pubmed.ncbi.nlm.nih.gov/4176291 ... t6+133c1fe